The problem with Medify is that right from the beginning they chose a path of lies, misrepresentations and broken promises. They would achieve much more with truthfulness, cautious assessments and full discloser. Their investors would respect them, wouldn't be disappointed, and it would be reflected in a much higher PPS by now.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.